pivalyloxymethyl butyrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pivalyloxymethyl butyrate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	60748
CHEMBL ID	100014
SCHEMBL ID	356482
MeSH ID	M0191821

Synonyms (31)

Synonym
37380-45-3
an 9 (ion exchanger)
122110-53-6
an-9
pivanex
((2,2-dimethylpropanoyl)oxy)methyl butanoate
brn 4861411
pivalyloxymethyl butyrate
an 9
butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester
butanoyloxymethyl 2,2-dimethylpropanoate
butyric acid 2,2-dimethyl-propionyloxymethyl ester
CHEMBL100014
butyric acid 2,2-dimethyl-propionyloxymethyl ester(an9)
unii-55vnk5440p
55vnk5440p ,
pivaloyloxymethyl butyrate
pivaloyloxymethylbutyrate
SCHEMBL356482
an-9;pivalyloxymethyl butyrate
J-004762
an-9, >=95% (hplc)
DTXSID40190818
(pivaloyloxy)methyl butyrate
AKOS030571025
DB05103
HY-120508
Q27261343
CS-0078203
BS-51881
F72881

Research Excerpts

Overview

Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid.

Excerpt	Reference	Relevance
"Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid. "	( Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Honma, Y; Kasukabe, T; Niitsu, N; Okabe-Kado, J; Umeda, M; Yamamoto-Yamaguchi, Y; Yokoyama, A, 2000)	2.02

Compound-Compound Interactions

Excerpt	Reference	Relevance
" The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas."	( In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Entin-Meer, M; Haas-Kogan, DA; Lamborn, KR; Nudelman, A; Rephaeli, A; VandenBerg, SR; Yang, X, 2007)	0.34

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID41063	Lethal dose was determined	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41064	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 100 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID247711	Concentration required for 50% inhibition of human HL-60 cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID154429	Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID41070	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 12.5 mg/kg	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID234601	T/C value was determined	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID247690	Concentration required for 50% inhibition of human PC-3 cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID41061	Effect on appearance of B16F10.9 colonies in semisolid agar	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41069	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 100 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID247712	Concentration required for 50% inhibition of human HT-29 cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID81447	Concentration required for 50% proliferation inhibition of human promyelocytic HL-60 cell line	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41066	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 25 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID247800	Concentration required for 50% inhibition of human HL-60 MX2 cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID247742	Concentration required for 50% inhibition of human MES-SA cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
AID41065	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 12.5 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41062	Inhibitory activity on growth of B16F10.9 melanoma cell line	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID217956	Concentration required for 50% proliferation inhibition of myelomonocytic WEHI cell line	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41068	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) was observed after administration of 50 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41072	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID41071	Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 25 mg/kg dose	1992	Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4	Novel anticancer prodrugs of butyric acid. 2.
AID3329	Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
AID247759	Concentration required for 50% inhibition of human MES-DX5 cell proliferation	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	9 (31.03)	18.2507
2000's	18 (62.07)	29.6817
2010's	1 (3.45)	24.3611
2020's	1 (3.45)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.15 (24.57)
Research Supply Index	3.50 (2.92)
Research Growth Index	4.64 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (6.67%)	5.53%
Reviews	3 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	3.24	6	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.71	3	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	3.14	1	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.31	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.02	1	dihydroxyanthraquinone	analgesic; antineoplastic agent
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	1.99	1	acyl fluoride	serine proteinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.14	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.02	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	7.4	2	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
trapoxin a trapoxin A: from Helicoma ambiens; structure given in first source. trapoxin A : A homodetic cyclic tetrapeptide constructed from L-phenylalanyl (x2), D-pipecolinyl and L-2-amino-8-oxo-9,10-epoxydecanoyl residues.	2.31	1	epoxide; homodetic cyclic peptide; ketone	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; fungal metabolite
4-aminophenylphosphate 4-aminophenylphosphate: RN refers to di-Ag salt; structure given in first source	2.39	2
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.03	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.31	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
decitabine [no description available]	2.02	1	2'-deoxyribonucleoside
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	3.14	1	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
diethoxyphosphoryloxymethyl butanoate diethoxyphosphoryloxymethyl butanoate: butyroyloxymethyl-diethyl phosphate antitumor cpd; structure in first source; do not confuse with AN 7 peptide complex	2.44	2

Condition	Indicated	Relationship Strength	Studies	Trials
B16 Melanoma [description not available]	0	1.98	1	0
Metastase [description not available]	0	2.41	2	0
Acute Promyelocytic Leukemia [description not available]	0	2.67	3	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.41	2	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	0	2.67	3	0
Craniofacial Abnormalities Congenital structural deformities, malformations, or other abnormalities of the cranium and facial bones.	0	2.31	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.13	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.13	1	0
Adult Spinal Muscular Atrophy [description not available]	0	2.13	1	0
Muscular Atrophy, Spinal A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)	0	2.13	1	0
Benign Neoplasms [description not available]	0	5.7	4	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	5.7	4	1
Leucocythaemia [description not available]	0	2.01	1	0
Granulocytic Leukemia [description not available]	0	2.69	3	0
Leukemia, Pre-B-Cell [description not available]	0	2.01	1	0
ATLL [description not available]	0	2.01	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.01	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	2.01	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	2.69	3	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	2.01	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	0	2.01	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	4.74	2	1
Lassitude [description not available]	0	3.4	1	1
Cancer of Lung [description not available]	0	5.22	4	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	6.74	2	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	3.4	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	0	5.22	4	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	3.4	1	1
Granulocytic Leukemia, Chronic [description not available]	0	2.03	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.03	1	0
Glial Cell Tumors [description not available]	0	2.03	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.03	1	0
Angiogenesis, Pathologic [description not available]	0	2.03	1	0
Cancer of Prostate [description not available]	0	2.03	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.03	1	0
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	0	1.99	1	0
Leukemia, Myeloid, Acute, M4 [description not available]	0	1.99	1	0
Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.	0	1.99	1	0
Germinoblastoma [description not available]	0	2	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	2	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	2	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	1	4	1	0
Adenocarcinoma, Basal Cell [description not available]	0	2	1	0
Breast Cancer [description not available]	0	2	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2	1	0

chemdatabank.com